398 related articles for article (PubMed ID: 34536819)
1. Distinct phosphorylation profiles of tau in brains of patients with different tauopathies.
Samimi N; Sharma G; Kimura T; Matsubara T; Huo A; Chiba K; Saito Y; Murayama S; Akatsu H; Hashizume Y; Hasegawa M; Farjam M; Shahpasand K; Ando K; Hisanaga SI
Neurobiol Aging; 2021 Dec; 108():72-79. PubMed ID: 34536819
[TBL] [Abstract][Full Text] [Related]
2. Patterns of hippocampal tau pathology differentiate neurodegenerative dementias.
Milenkovic I; Petrov T; Kovacs GG
Dement Geriatr Cogn Disord; 2014; 38(5-6):375-88. PubMed ID: 25195847
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
4. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
[TBL] [Abstract][Full Text] [Related]
5. Anti-tau phospho-specific Ser262 antibody recognizes a variety of abnormal hyper-phosphorylated tau deposits in tauopathies including Pick bodies and argyrophilic grains.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):658-64. PubMed ID: 12410387
[TBL] [Abstract][Full Text] [Related]
6. [Neuropathology of tauopathy].
Yoshida M
Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
[TBL] [Abstract][Full Text] [Related]
7. Argyrophilic grain disease and Alzheimer's disease are distinguished by their different distribution of tau protein isoforms.
Tolnay M; Sergeant N; Ghestem A; Chalbot S; De Vos RA; Jansen Steur EN; Probst A; Delacourte A
Acta Neuropathol; 2002 Oct; 104(4):425-34. PubMed ID: 12200631
[TBL] [Abstract][Full Text] [Related]
8. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies.
Vingtdeux V; Davies P; Dickson DW; Marambaud P
Acta Neuropathol; 2011 Mar; 121(3):337-49. PubMed ID: 20957377
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.
Rawat P; Sehar U; Bisht J; Selman A; Culberson J; Reddy PH
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361631
[TBL] [Abstract][Full Text] [Related]
10. Selective tau tyrosine nitration in non-AD tauopathies.
Reyes JF; Geula C; Vana L; Binder LI
Acta Neuropathol; 2012 Jan; 123(1):119-32. PubMed ID: 22057784
[TBL] [Abstract][Full Text] [Related]
11. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Arai T; Ikeda K; Akiyama H; Tsuchiya K; Iritani S; Ishiguro K; Yagishita S; Oda T; Odawara T; Iseki E
Acta Neuropathol; 2003 May; 105(5):489-98. PubMed ID: 12677450
[TBL] [Abstract][Full Text] [Related]
12. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy brains.
Malarte ML; Gillberg PG; Kumar A; Bogdanovic N; Lemoine L; Nordberg A
Mol Psychiatry; 2023 Mar; 28(3):1272-1283. PubMed ID: 36447011
[TBL] [Abstract][Full Text] [Related]
13. Function and regulation of cis P-tau in the pathogenesis and treatment of conventional and nonconventional tauopathies.
Wang R; Lu KP; Zhou XZ
J Neurochem; 2023 Sep; 166(6):904-914. PubMed ID: 37638382
[TBL] [Abstract][Full Text] [Related]
14. Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease.
Ando K; Tomimura K; Sazdovitch V; Suain V; Yilmaz Z; Authelet M; Ndjim M; Vergara C; Belkouch M; Potier MC; Duyckaerts C; Brion JP
Neurobiol Dis; 2016 Oct; 94():32-43. PubMed ID: 27260836
[TBL] [Abstract][Full Text] [Related]
15. Specific post-translational modifications of soluble tau protein distinguishes Alzheimer's disease and primary tauopathies.
Kyalu Ngoie Zola N; Balty C; Pyr Dit Ruys S; Vanparys AAT; Huyghe NDG; Herinckx G; Johanns M; Boyer E; Kienlen-Campard P; Rider MH; Vertommen D; Hanseeuw BJ
Nat Commun; 2023 Jun; 14(1):3706. PubMed ID: 37349319
[TBL] [Abstract][Full Text] [Related]
16. Tauopathies as clinicopathological entities.
Irwin DJ
Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(0 1):S29-33. PubMed ID: 26382841
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Blanco R; Carmona M; Ribera R; Goutan E; Puig B; Rey MJ; Cardozo A; Viñals F; Ribalta T
Brain Pathol; 2001 Apr; 11(2):144-58. PubMed ID: 11303790
[TBL] [Abstract][Full Text] [Related]
18. Tau prions from Alzheimer's disease and chronic traumatic encephalopathy patients propagate in cultured cells.
Woerman AL; Aoyagi A; Patel S; Kazmi SA; Lobach I; Grinberg LT; McKee AC; Seeley WW; Olson SH; Prusiner SB
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):E8187-E8196. PubMed ID: 27911827
[TBL] [Abstract][Full Text] [Related]
19. Imaging biomarkers in tauopathies.
Dani M; Edison P; Brooks DJ
Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S26-8. PubMed ID: 26299160
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease.
Ferrer I; Barrachina M; Tolnay M; Rey MJ; Vidal N; Carmona M; Blanco R; Puig B
Brain Pathol; 2003 Jan; 13(1):62-78. PubMed ID: 12580546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
